Pharmas turn up the heat on Novartis
Another potential rival for Novartis’ lucrative eye drug Lucentis has arrived in Australia, with the TGA approving Lupin’s biosimilars Simulara, Solentis, and Zivra.
To see the whole article, log in or create an account.